CT and MRI Contrast Risks: What Patients Should Know Before and After a Contrast-Enhanced Scan (2026)

By Editorial Team
Computed tomography (CT) and magnetic resonance imaging (MRI) scans have revolutionized modern medicine, enabling doctors to detect cancers, infections, vascular diseases, and internal injuries with remarkable accuracy. In many cases, these scans are performed using contrast agents, special substances injected into the bloodstream to improve image quality and diagnostic precision.

While contrast-enhanced imaging is generally considered safe, growing public awareness and scientific discussion have raised important questions about potential side effects, long-term tissue retention, kidney safety, and informed consent. Understanding both the benefits and risks can help patients make informed decisions before undergoing a contrast-enhanced CT or MRI scan.

What Is Contrast Material?

Contrast agents are pharmaceutical substances administered before or during imaging studies to improve visualization of organs, blood vessels, and abnormal tissues.

There are two major types:

  • Iodinated contrast agents used primarily in CT scans.
  • Gadolinium-based contrast agents (GBCAs) used in MRI scans.

These agents help radiologists identify tumors, inflammation, infections, bleeding, vascular abnormalities, and treatment responses that might otherwise be difficult to detect.

Why Contrast Matters in Cancer Detection

For oncology patients, contrast-enhanced imaging is often essential.

Doctors rely on contrast scans to:

  • Detect primary tumors.
  • Identify metastatic spread.
  • Evaluate treatment response.
  • Guide surgery and radiation planning.
  • Monitor disease progression.

In many situations, a non-contrast scan may miss clinically significant findings. This is why radiologists frequently recommend contrast despite its potential risks.

Common Side Effects of Contrast Agents

Most patients tolerate contrast agents without major complications. However, side effects can occur.

Mild Side Effects

  • Nausea
  • Headache
  • Warm flushing sensation
  • Metallic taste
  • Dizziness
  • Mild itching

These symptoms are usually temporary and resolve without treatment.

Moderate to Severe Reactions

Although uncommon, some individuals may experience:

  • Hives
  • Significant allergic reactions
  • Shortness of breath
  • Low blood pressure
  • Anaphylaxis

Severe reactions are rare but require immediate medical attention.

Gadolinium Retention: What Does the Science Say?

One of the most debated issues in recent years involves gadolinium retention following MRI examinations.

Multiple studies have demonstrated that trace amounts of gadolinium may remain in various tissues after MRI scans, including:

  • Brain tissue
  • Bones
  • Skin
  • Liver
  • Kidneys

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) acknowledge that gadolinium retention occurs following repeated exposure.

However, an important distinction must be made:

Retention does not automatically mean toxicity.

While gadolinium deposits have been detected in tissues, researchers have not conclusively established that retained gadolinium causes chronic symptoms in most patients with normal kidney function.

Understanding Gadolinium Deposition Disease (GDD)

Some patients report persistent symptoms after gadolinium-enhanced MRI scans, including:

  • Joint pain
  • Muscle pain
  • Brain fog
  • Fatigue
  • Burning sensations
  • Skin changes

These symptoms have been described under the term Gadolinium Deposition Disease (GDD).

Currently, GDD remains controversial within mainstream medicine because causation has not been definitively proven. Researchers continue investigating whether a subset of patients may be particularly susceptible to gadolinium-related adverse effects.

Kidney Function and Contrast Safety

Kidney health plays a critical role in contrast safety.

Both iodinated contrast and gadolinium contrast are primarily eliminated through the kidneys. Patients with advanced kidney disease face increased risks of complications.

Contrast-Induced Acute Kidney Injury (CI-AKI)

Iodinated CT contrast has historically been associated with contrast-induced acute kidney injury, especially among:

  • Patients with chronic kidney disease
  • Diabetes patients
  • Elderly individuals
  • Hospitalized patients

Recent research suggests the risk may be lower than previously believed, but caution remains warranted in high-risk populations.

Nephrogenic Systemic Fibrosis (NSF)

Patients with severe kidney dysfunction are at risk of developing nephrogenic systemic fibrosis, a rare but serious condition linked to certain gadolinium-based contrast agents.

Because of this risk, many imaging centers routinely check kidney function before administering contrast.

Should You Be Concerned About Multiple Contrast Scans?

Patients undergoing cancer surveillance or chronic disease monitoring may receive numerous contrast-enhanced scans over many years.

Current evidence suggests that:

  • Most patients tolerate repeated contrast exposure well.
  • Modern macrocyclic gadolinium agents appear safer than older linear agents.
  • Kidney function should be monitored periodically.
  • Each scan should have a clear medical justification.

Repeated imaging should always be guided by a risk-benefit assessment rather than performed routinely without clinical necessity.

Questions to Ask Before a Contrast Scan

Patients should feel empowered to discuss contrast use with their healthcare providers.

Consider asking:

  • Why is contrast necessary?
  • Would a non-contrast study provide similar information?
  • Which contrast agent will be used?
  • What are the known risks?
  • Have I had prior reactions to contrast?
  • Do I need kidney function testing beforehand?
  • Are there alternative imaging options?

What to Do After Receiving Contrast

For most healthy individuals, contrast agents are eliminated naturally within hours to days.

After the scan:

  • Stay adequately hydrated unless medically restricted.
  • Monitor for delayed allergic reactions.
  • Report unusual symptoms to your healthcare provider.
  • Maintain records of previous contrast reactions.

Patients with kidney disease should follow any additional instructions provided by their medical team.

The Importance of Informed Consent

One of the most important issues surrounding contrast-enhanced imaging is informed consent.

Patients deserve clear explanations regarding:

  • The purpose of the scan.
  • The expected diagnostic benefit.
  • Potential risks and side effects.
  • Available alternatives.

Transparent communication helps patients participate meaningfully in medical decision-making while maintaining confidence in the diagnostic process.

Bottom Line

CT and MRI contrast agents have helped save countless lives by improving the detection and monitoring of cancer, cardiovascular disease, infections, and other serious conditions. For most patients, the benefits of medically indicated contrast-enhanced imaging significantly outweigh the risks.

Nevertheless, contrast agents are not completely risk-free. Concerns regarding gadolinium retention, kidney safety, allergic reactions, and long-term effects warrant ongoing research and thoughtful patient education.

The most balanced approach is neither fear nor blind acceptance. Instead, patients should engage in informed discussions with their healthcare providers, understand the purpose of the scan, and carefully weigh potential benefits against individual risks.

References

  1. American College of Radiology (ACR). Manual on Contrast Media.
  2. U.S. Food and Drug Administration (FDA). Gadolinium-Based Contrast Agents Safety Communications.
  3. European Medicines Agency (EMA). Gadolinium Contrast Agent Reviews.
  4. National Kidney Foundation. Contrast Dye and Kidney Disease.
  5. Mayo Clinic. MRI and CT Contrast Agents: Benefits and Risks.
  6. Cleveland Clinic. Gadolinium Contrast: Safety and Side Effects.
  7. McDonald RJ, et al. Intracranial Gadolinium Deposition after Contrast-Enhanced MRI. Radiology.
  8. Kanda T, et al. Gadolinium-Based Contrast Agent Accumulation and Toxicity. Journal of Magnetic Resonance Imaging.
  9. https://www.theepochtimes.com/health/what-no-one-tells-you-before-or-after-a-ct-or-mri-with-contrast-6026564

Disclaimer: This article is for educational purposes only and should not be construed as medical advice. Patients should consult qualified healthcare professionals regarding diagnostic imaging decisions and individual health concerns.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: May 2026 Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Table of Contents: Editor's Preface Introduction Fenbendazole and Iverme...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Last revised: June 2026 Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Ivermectin combined with benzimidazoles (fenbendazole, mebendazole) represents an emerging area of repurposed oncology pharmacology. All protocols require physician supervision. Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dos...
Read more

Fenbendazole and Ivermectin for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
Summary Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited effective therapies and poor survival, especially in stage 4 disease. Repurposing antiparasitic agents such as fenbendazole and ivermectin has garnered interest due to their demonstrated anti-cancer properties in preclinical studies. Methods: We reviewed and synthesized 35 detailed case reports from 2022 to 2026 documenting the clinical use of fenbendazole and ivermectin, alone or in combination with standard therapies, in patients with advanced pancreatic cancer. Tumor markers, imaging outcomes, and clinical responses were analyzed alongside mechanistic literature. Results: Across cases, patients exhibited marked reductions in CA19-9 tumor markers (often >70%), significant tumor shrinkage on imaging, and improved clinical status. Responses were observed even in chemotherapy-resistant and metastatic disease. Mechanistic studies support multiple anti-cancer effects of...
Read more

Archive

Show more